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Oxazaphosphorines are a class of DNA alkylating agents. The aim of the present study was to
compare the possible influence of three new generation oxazaphosphorines, D-17272
(mafosfamide cyclohexylamine salt), D-18864 (4-hydro-peroxy-cyclophosphamide), and
D-19575 (glufosfamide, $-D-glucose-isophosphoramide mustard) on DNA damage induction
in the human histiocytic lymphoma U937 cells. The flow cytometry APO-BRDUTM assay,
based on the TUNEL method, was used for the in situ detection of DNA strand breaks. After
exposure of U937 cells to the oxazaphosphorines, the patterns of temporary changes in the
frequency of TUNEL positive U937 cells, expressing DNA breakage, were determined. The
effects of the oxazaphosphorines on U937 cells were dependent on the agent tested and its
dose, and the time intervals after the drug application. The different potential of D-17272,
D-18864 and D-19575 to induce DNA strand breakage in the human histiocytic lymphoma
U937 cells was shown.
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Oxazaphosphorines belong to a class of antican-
cer alkylating agents. The oxazaphosphorines are
very useful and effective in the treatment of a wide
variety of hematological and non-hematological
malignancies. These therapeutic drugs include the
commonly used cyclophosphamide and ifosfa-
mide (BROCK 1989; ADIS INTERNATIONAL LIMITED
2005; ZHANG et al. 2005a, 2005b). Recently, ad-
ditional oxazaphosphorine derivatives, such as
mafosfamide cyclohexylamine salt, 4-hydro-
peroxy-cyclophosphamide and glufosfamide, have
been synthesized and tested for the improved ac-
tivity against different types of cancer cells
(ENGEL et al. 2000; SEKER et al. 2000; ZHANG et
al. 2005a; MISIURA 2006; LIANG et al. 2007).
These novel oxazaphosphorines, and especially
glufosfamide, have attracted much attention in a
broad spectrum of cancer therapy. The modes of
their action are still under experimental and clini-
cal investigations (BRIASOULIS et al. 2000, 2003;
BRÖKER & GIACCONE 2002; STYCZYÑSKI et al.
2002a, 2002b; VAN DEN BENT et al. 2003;
DOLLNER et al. 2004; GIACCONE et al. 2004;
ZHANG et al. 2005a, 2005b; AMMONS et al. 2007;
CHIOREAN et al. 2008; GOLDSTEIN et al. 2008;
MAZUR et al. 2008a, 2008b; CIULEANU et al.
2009).
There is a general consensus that DNA is the
main target for a large number of anticancer drugs.
The oxazaphosphorines are accepted to be DNA
damaging agents. A better understanding of the ac-
tion of these alkylating agents on DNA molecules
of cancer cells is important for their optional use in
chemotherapy (SEKER et al. 2000; BECKER et al.
2002).
_______________________________________
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The aim of the present study was to compare the
potential of three new generation oxazaphosphorines
to induce DNA breakage in the human histiocytic
lymphoma U937 cells. The in situ induction of
DNA strand breaks in U937 cells subjected to the
exposure to mafosfamide cyclohexylamine salt,
4-hydro-peroxy-cyclophosphamide and glufosfa-
mide, was analyzed using the TUNEL method.
Material and Methods
Cells
Human histiocytic lymphoma U937 cells
(American Type Culture Collection, Rockville,
MD, USA) were maintained in RPMI 1640 (Gibco
BRL Life Technologies) supplemented with 10%
fetal calf serum (GIBCO BRL Life Technologies),
2 mM L-glutamine (Sigma Aldrich), and antibiotic
antimycotic solution (Sigma Aldrich) containing
20 units of penicillin, 20 Fg streptomycin and 0.05
Fg amphotericin B. U937 cells were passaged
every third day, by diluting to a concentration of
5x105 cells/ml medium, and the cells grew expo-
nentially at 37oC in an atmosphere of 5% CO2 in air
(HERAcell incubator, KendroLab). The cultures
were periodically tested for Mycoplasma infec-
tion.
Chemicals
Mafosfamide cyclohexylamine salt (D-17272, CAS
No. 84210-80-0), 4-hydro-peroxy-cyclophosphamide
(D-18864, CAS No. 39800-16-3) and glufosfa-
mide (D-19575, $-D-glucose-isophosphoramide
mustard, CAS No. 132682-98-5) were obtained
from NIOMECH (Bielefeld, Germany). D-17272,
D-18864 and D-19575 were dissolved in aqua pro
injectione (Polpharma, Poland). All solutions
were freshly prepared directly before treatment of
U937 cells.
Drug doses and cell treatment
After a dilution of the cell suspension to a den-
sity of 15x104 cells/ml, U937 cells were subjected
to 30 min exposure to the oxazaphosphorine drug.
D-18864 was given at a dose of 5 Fg/ml medium,
D-19575 at a dose of 50 Fg/ml medium, and
D-17272 was applied at doses 5Fg/ml and 50 g/ml
medium. The control material consisted of un-
treated cells. After 30 min treatment with the
oxazaphosphorine agent, U937 cells were centri-
fuged for 10 min at 1000 rpm and the supernatant
was discarded. Then the cells were washed in 2 ml
of PBS (BioMed) and pelletted by centrifugation
for 7 min. The wash and centrifugation were re-
peated once more and the cells resuspended in 5 ml
of the complete RPMI 1640 medium.
Preparation procedure and fixation of cells
Samples of the cell suspension were taken at
24h, 48h and 72h after drug application. After 10
min centrifugation at 1000 rpm, and discarding the
supernatant, the cells were washed twice in 2 ml of
PBS and pelletted by centrifugation for 7 min.
U937 cells were flushed out with PBS and dis-
persed by gentle pipetting. Finally, the cells were
suspended in 500 Fl of PBS. After adding 5 ml of
1% (w/v) formaldehyde (Lach-Ner) in PBS, the
cell suspension was placed on ice for 15 min.
Then, U937 cells were centrifuged for 7 min at
1000 rpm and the supernatant was discarded. The
cells were washed in 2 ml of PBS and pelletted by
centrifugation. The wash and centrifugation were
repeated once more. The cells were resuspended in
500 Fl of PBS, and after adding 5 ml of ice-cold
70 % (v/v) ethanol, stored at -20oC until use.
APO-BRDUTM assay
The APO-BRDUTM Kit (Calbiochem), a two
color staining method for labeling DNA breaks
and total cellular DNA was used. The 3’ OH ter-
mini in the strand breaks can be analyzed by at-
taching FITC (fluorescein isothiocyanate)-labeled
5-bromo-2’-deoxyuridine 5’-triphosphate nucleo-
tides (Br-dUTP), in a reaction catalyzed by exoge-
nous terminal deoxynucleotidyl transferase (TdT).
This reaction is known as TUNEL from TdT-
mediated dUTP nick-end labeling. The incorpora-
tion of Br-dUTP into DNA strand breaks, detected
by FITC-conjugated anti-BrdU antibody, is com-
bined with staining of DNA with propidium iodide
(PI) (DAR¯YNKIEWICZ et al. 2001). The kit con-
sisted of washing, reaction, and rinsing buffers for
processing individual steps in the assay, TdT, Br-
dUTP, fluorescein labeled anti-BrdU antibody for
labeling DNA breaks and PI/RNase A solution for
counter staining the total DNA.
APO-BRDUTM protocol
The leukemic cell suspension was centrifuged
for 10 min at 1000 rpm and the 70% ethanol was
removed by aspiration. The cell pellet was resus-
pended with 1 ml of wash buffer, centrifuged for
7 min at 1000 rpm and the supernatant removed.
The wash buffer treatment was repeated and the
cell pellet resuspended in 50 Fl of the DNA label-
ing solution containing 10 Fl of TdT reaction
buffer, 0.75 Fl of TdT enzyme, 8 Fl of Br-dUTP,
L. MAZUR et al.16
and 32.25 Fl of distilled H2O. The cells were incu-
bated in the DNA labeling solution for 60 min at
37oC in a temperature controlled bath. At the end
of incubation time, 1 ml of rinse buffer was added
to each tube, the cells centrifuged for 7 min at 1000
rpm and the supernatant removed by aspiration.
Cell rinsing with 1 ml of the rinse buffer was re-
peated, and then the cell pellet was resuspended in
100 Fl of the antibody solution containing 5 Fl of
fluorescein labeled anti-BrdU antibody suspended
in 95 Fl of the rinse buffer. The cells were incu-
bated with the fluoresceinated antibody solution in
the dark for 30 min at room temperature. Then, 300
Fl of the propidium iodide/RNase A solution was
added to the tube containing 100Fl of the antibody
solution, and the cells were incubated in the dark
for 30 min at room temperature.
Flow cytometry analysis of leukemic cells
The fluorescence of individual U937 cells was
measured by a flow cytometer (FACS Calibur,
Beckton Dickinson). Green fluorescence of
FITC-conjugated anti-BrdU antibody was meas-
ured at 530-nm and red fluorescence of propidium
iodide at >600 nm. At least 5 000 cells were ana-
lyzed per one sample.
Results
The effects of three oxazaphosphorines,
D-17272, D-18864, and D-19575, on DNA degra-
dation in U937 cells, were compared. Using the
flow cytometry APO-BRDUTM assay, based on
the in situ detection of DNA strand breaks, tempo-
rary changes in the frequency of TUNEL positive
U937 cells were determined at 24h, 48h, and 72h
after the application of the oxazaphosphorine agent
(Table 1, Fig. 1).
The frequency of DNA strand breaks was found
to be smaller in U937 cells treated with D-17272,
at a dose of 5 Fg/ml medium, than in the cells ex-
posed to D-18864, at the same dose. The frequency
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Table 1






No.       drug given    drug dose
Frequency of U937 cells  expressing DNA strand breaks
Mean ± SD Mean ± SD Mean ± SD
I            D-18864       5 Fg/ml
2, 3, 4, 5, 72h
38.27 ± 1.12
2, 3, 4, 5
42.67 ± 5.41
2, 3, 4, 5, 24h
47.59 ± 6.91
II           D-17272       5 Fg/ml
1, 5, 48h, 72h
7.91 ± 1.91
1, 3, 5, 24h
5.41 ± 0.42
1, 3, 4, 5, 24h
5.01 ± 0.80
III         D-17272     50 Fg/ml
1, 5, 48h, 72h
11.49 ± 1.95
1, 2, 4, 5, 24h, 72h
63.83 ± 4.61
1, 2, 4, 5, 24h, 48h
76.02 ± 2.71
IV         D-19575     50 Fg/ml
1, 5
9.11 ± 2.56
1, 3, 5, 72h
6.76 ± 1.42
1, 2, 3, 5, 48h
11.79 ± 1.70
V                control 1, 2, 3, 42.23 ± 0.16
1, 2, 3, 4
2.48 ± 0.21
1, 2, 3, 4
2.29 ± 0.39
Statistically significant differences at P<0.05
Differences between groups: different from Group I – 1, Group II – 2; Group III – 3; Group IV – 4; Group V – 5.
Differences within each group: different from 24h – 24h; 48h – 48h; 72h – 72h.
of TUNEL positive cells, assessed at 48h and 72h
after the exposure of U937 cells to D-17272, ap-
peared to be respectively greater when the
oxazaphosphorine agent was applied at the higher
dose of 50 Fg/ml than at the lower one of 5 Fg/ml
medium. The frequency of DNA strand breaks ob-
served at 48h and 72h after D-19575 application,
at a dose of 50 Fg/ml medium, was respectively
smaller as compared with that found after the treat-
ment of U937 cells with D-17272, at the same
dose. In comparison with the controls, the fre-
quency of U937 cells expressing DNA strand
breaks increased in all remaining experimental
groups at all time intervals after the oxazaphos-
phorine application.
Discussion
The results of the present study have shown the
influence of three new generation oxazaphos-
phorines, D-17272, D-18864 and D-19575, on
DNA breakage induction in the human histiocytic
lymphoma U937 cells. The different patterns of
temporary changes in the frequency of U937 cells
expressing DNA strand breaks, were found at 24,
48 and 72h after the alkylating drug application.
DNA degradation was dependent on the compound
tested and its dose, and the time intervals after the
exposure of U937 cells to the oxazaphosphorine
agent.
The mechanisms of action of D-17272, D-18864
and D-19575, have not yet been completely explained
(BODY & YULE 2000; ZHANG et al. 2005a). How-
ever, it is known that D-17272, mafosfamide cy-
clohexylamine salt, generates its active principle
4-hydroxy-cyclophosphamide (4-OH-CP) which de-
grades to phosphoramide mustard and acrolein.
D-18864, that is 4-hydro-peroxy-cyclophosphamide,
generates 4-OH-CP. Thus, phosphoramide mus-
tard and acrolein are the major ultimate alkylating
agents of the pro-drugs, D-17272 and D-18864
Fig. 1. In situ detection of DNA strand breaks in U937 cells after application of D-17272, D-18864 and D-19575, using flow
cytometry APO-BRDUTMassay. Histograms of FITC green fluorescence intensities of U937 cells treated with: D-18864
(5 Fg/ml medium) – yellow line; D-17272 (5 Fg/ml medium) – red line; D-17272 (50 Fg/ml medium) – green line; D-19575
(50 Fg/ml medium) – orange line. FL1-H – BrdUTP-FITC.
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24h 48h 72h
(BODY & YULE 2000; KEHRER & BISWAL 2000;
ZHANG et al. 2005a, 2005b). Unlike these pro-
drugs, D-19575, $-D-glucose-isophosphoramide
mustard, contains the directly active alkylating
moiety, isophosphoramide mustard (IPM) linked
to a $-D-glucose-molecule. Inside the cell, D-19575
hydrolyzes to IPM and $-D-beta-D-glucose
(POHL et al. 1995; VEYHL et al. 1998; ENGEL et al.
2000; LIANG et al. 2007).
The cytotoxic effects of the oxazaphosphorines
are thought to be dependent mainly on DNA alky-
lating properties. The active alkylating agents can
bind to a variety of molecules, but the most impor-
tant site of their binding is DNA. These active
compounds can react with phosphate, amino, and
hydroxyl groups of the bases of nucleic acids. The
ultimate alkylating mustards from the oxazaphos-
phorines are the predominant metabolites that
cause DNA damage such as adducts and crosslinks,
and DNA strand breaks (SEKER et al. 2000;
BECKER et al. 2002; ZHANG et al. 2005b). It is
known that DNA damage can trigger programmed
cell death. However, the mechanisms responsible
for the activation of cellular death pathways lead-
ing to programmed cell death, due to the adduct
and crosslink formation, and DNA breakage induc-
tion, have yet to be fully elucidated (GUIMARAES
& LINDEN 2004; ZHANG et al. 2005a, 2005b;
GOLDSTEIN et al. 2008).
The modes of action of D-17272, D-18864 and
D-19575 are suggested to be closely related to the
pharmacokinetic, pharmacodynamic, and cyto-
toxic properties of these three oxazaphosphorine
agents. It is believed that the oxazaphosphorine
metabolism and transport have a major impact on
pharmacokinetic variability, the pharmacokinetic-
-pharmacodynamic relationship, and cytotoxicity
(MOORE 1991; POHL et al. 1995; STUBEN et al.
1996; VEYHL et al. 1998; BODY & YULE 2000;
ENGEL et al. 2000; BRIASOULIS et al. 2003;
GIACCONE et al. 2004; ZHANG et al. 2005a, 2005b).
To summarize, the oxazaphosphorines D-17272,
D-18864 and D-19575 distinctly affect DNA break-
age formation in the human histiocytic lymphoma
U937 cells. The results of the present investigation
are the first data comparing the potential of these
three alkylating agents, mafosfamide cyclohexy-
lamine salt, 4-hydro-peroxy-cyclophosphamide,
and glufosfamide, to induce DNA strand breaks in
the malignant hematopoietic cells. An elucidation
of the mechanisms and processes responsible for
the different extent of DNA damage occurring in
various types of cancer cells, following their expo-
sure to the oxazaphosphorine agents, can facilitate
the development of new therapeutic strategies.
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